https://us.gsk.com/en-us/ 2026-04-01T15:57:37.683Z https://us.gsk.com/en-us/company/ 2026-03-30T12:15:17.917Z https://us.gsk.com/en-us/company/purpose-strategy-and-culture/ 2026-03-30T12:58:50.063Z https://us.gsk.com/en-us/company/respiratory-immunology-and-inflammation/ 2026-03-30T12:49:36.717Z https://us.gsk.com/en-us/company/oncology/ 2026-02-26T17:12:11.023Z https://us.gsk.com/en-us/company/oncology/myelofibrosis/ 2025-10-15T15:32:47.753Z https://us.gsk.com/en-us/company/oncology/ovarian-cancer/ 2025-09-16T10:11:18.163Z https://us.gsk.com/en-us/company/oncology/endometrial-cancer/ 2025-12-23T16:05:03.56Z https://us.gsk.com/en-us/company/oncology/multiple-myeloma/ 2025-09-10T08:52:34.51Z https://us.gsk.com/en-us/company/oncology/rectal-cancer/ 2026-02-25T13:32:21.04Z https://us.gsk.com/en-us/company/hiv/ 2026-03-30T12:48:09.28Z https://us.gsk.com/en-us/company/infectious-diseases/ 2026-03-30T12:57:53.237Z https://us.gsk.com/en-us/company/infectious-diseases/vaccines/ 2025-09-04T13:21:42.287Z https://us.gsk.com/en-us/company/infectious-diseases/flu/ 2025-09-04T13:32:23.45Z https://us.gsk.com/en-us/company/infectious-diseases/shingles-herpes-zoster/ 2026-02-04T11:10:37.003Z https://us.gsk.com/en-us/company/infectious-diseases/rsv-respiratory-syncytial-virus/ 2025-09-04T16:30:21.763Z https://us.gsk.com/en-us/company/infectious-diseases/meningitis/ 2025-09-04T13:31:17.477Z https://us.gsk.com/en-us/innovation/ 2026-03-30T12:24:33.94Z https://us.gsk.com/en-us/innovation/therapeutic-areas/ 2026-03-30T12:27:05.263Z https://us.gsk.com/en-us/innovation/technologies/ 2025-09-04T16:08:07.877Z https://us.gsk.com/en-us/innovation/clinical-studies/ 2025-07-10T19:23:39.31Z https://us.gsk.com/en-us/innovation/clinical-studies/representative-clinical-trials/ 2025-07-10T19:21:12.657Z https://us.gsk.com/en-us/products/ 2025-08-28T15:11:48.113Z https://us.gsk.com/en-us/responsibility/ 2026-03-30T12:28:22.813Z https://us.gsk.com/en-us/responsibility/inclusion/ 2025-12-15T15:18:13.223Z https://us.gsk.com/en-us/responsibility/us-charitable-investments/ 2026-03-11T11:29:52.467Z https://us.gsk.com/en-us/responsibility/us-charitable-investments/charitable-grants/ 2025-06-19T15:53:12.703Z https://us.gsk.com/en-us/responsibility/ethical-standards/ 2025-09-04T16:36:13.773Z https://us.gsk.com/en-us/media/ 2026-01-12T18:08:08.803Z https://us.gsk.com/en-us/media/press-releases/ 2025-11-11T14:24:51.52Z https://us.gsk.com/en-us/media/press-releases/students-step-into-the-role-of-athletic-trainers-cardiologists-dietitians-and-more-with-free-summer-science-program/ 2025-06-27T12:10:39.22Z https://us.gsk.com/en-us/media/press-releases/summer-will-be-out-of-this-world-for-philly-area-students-with-gsk-science-in-the-summer-the-science-of-space/ 2025-06-19T15:47:51.927Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-new-efficacy-data-for-fluarix-quadrivalent-influenza-vaccine-in-children-6-months-through-35-months-of-age/ 2025-06-19T15:47:51.133Z https://us.gsk.com/en-us/media/press-releases/sensodyne-rapid-relief-launches-in-the-united-states/ 2025-06-19T15:47:50.1Z https://us.gsk.com/en-us/media/press-releases/summer-will-be-out-of-this-world-for-elementary-school-students-with-gsk-science-in-the-summer-and-the-science-of-space/ 2025-06-19T15:47:49.093Z https://us.gsk.com/en-us/media/press-releases/local-nonprofits-make-a-bigger-impact-with-40-000-award-from-gsk-in-greater-philadelphia-region/ 2025-06-19T15:47:47.987Z https://us.gsk.com/en-us/media/press-releases/local-nonprofits-make-a-bigger-impact-with-40-000-award-from-gsk-in-the-triangle-region-of-north-carolina/ 2025-06-19T15:47:46.48Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-college-scholarships-to-triangle-region-nc-students-who-have-overcome-adversity-to-pursue-their-dreams/ 2025-06-19T15:47:45.113Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-college-scholarships-to-philadelphia-students-who-have-overcome-adversity-to-pursue-their-dreams/ 2025-06-19T15:47:43.993Z https://us.gsk.com/en-us/media/press-releases/gsk-science-in-the-summer-classes-kick-off-across-the-nation/ 2025-06-19T15:47:42.523Z https://us.gsk.com/en-us/media/press-releases/gsk-ships-2018-19-seasonal-influenza-vaccines-for-us-market/ 2025-06-19T15:47:41.283Z https://us.gsk.com/en-us/media/press-releases/positive-results-from-harmony-outcomes-study-of-albiglutide-published-in-the-lancet-1/ 2025-06-19T15:47:40.18Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/ 2025-06-19T15:47:38.647Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-new-efficacy-and-safety-data-of-an-anti-gm-csf-antibody-in-patients-with-rheumatoid-arthritis/ 2025-06-19T15:47:36.867Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-q3-sales-of-81-billion-plus3-aer-plus6-cer/ 2025-06-19T15:47:34.713Z https://us.gsk.com/en-us/media/press-releases/once-daily-trelegy-ellipta-gains-expanded-copd-indication-in-europe/ 2025-06-19T15:47:33.467Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-triangle-nonprofits-making-a-dynamic-impact-on-health-outcomes/ 2025-06-19T15:47:31.923Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-winners-of-2016-discovery-fast-track-boston-challenge/ 2025-06-19T15:47:30.877Z https://us.gsk.com/en-us/media/press-releases/gsk-consumer-healthcare-launches-flonase-sensimist-allergy-relief-nationwide/ 2025-06-19T15:47:29.51Z https://us.gsk.com/en-us/media/press-releases/get-hype-philly-thrilled-to-win-a-healthy10-award/ 2025-06-19T15:47:28.517Z https://us.gsk.com/en-us/media/press-releases/science-is-a-slam-dunk-with-gsk-science-in-the-summer/ 2025-06-19T15:47:27.423Z https://us.gsk.com/en-us/media/press-releases/local-nonprofits-making-the-triangle-healthier-can-win-40-000/ 2025-06-19T15:47:26.183Z https://us.gsk.com/en-us/media/press-releases/local-nonprofits-making-philly-healthier-can-win-40-000/ 2025-06-19T15:47:24.647Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-fluarix-quadrivalent-influenza-vaccine-for-infants-6-months-and-older/ 2025-06-19T15:47:23.537Z https://us.gsk.com/en-us/media/press-releases/derek-hough-sends-social-media-stars-the-eh-bee-family-on-cross-country-road-trip-to-reimagine-what-s-possible-despite-allergies/ 2025-06-19T15:47:21.833Z https://us.gsk.com/en-us/media/press-releases/gsk-invests-139-million-to-expand-production-capacity-for-benlysta-belimumab-in-rockville-md/ 2025-06-19T15:47:20.273Z https://us.gsk.com/en-us/media/press-releases/gsk-demonstrates-leadership-in-respiratory-medicine-at-ats-2017-with-over-50-abstracts-from-across-comprehensive-portfolio/ 2025-06-19T15:47:17.97Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-college-scholarships-to-triangle-region-nc-students-who-have-overcome-adversity-to-pursue-their-dreams-1/ 2025-06-19T15:47:16.037Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-college-scholarships-to-philadelphia-students-who-have-overcome-adversity-to-pursue-their-dreams-1/ 2025-06-19T15:47:14.81Z https://us.gsk.com/en-us/media/press-releases/gsk-ships-2017-18-seasonal-influenza-vaccines-for-us-market/ 2025-06-19T15:47:13.747Z https://us.gsk.com/en-us/media/press-releases/gsk-supports-healthy-eating-after-school-with-vetri-cooking-lab/ 2025-06-19T15:47:12.597Z https://us.gsk.com/en-us/media/press-releases/gsk-consumer-healthcare-and-cvs-health-partner-to-support-the-american-lung-association-during-lung-cancer-awareness-month/ 2025-06-19T15:47:11.493Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-new-data-at-acr-for-benlysta-belimumab-for-subcutaneous-use-sc-showing-reduced-need-to-increase-corticosteroid-dose/ 2025-06-19T15:47:10.607Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-new-data-at-acr-for-benlysta-belimumab-for-subcutaneous-use-sc-showing-improvement-in-multiple-organ-domains/ 2025-06-19T15:47:09.563Z https://us.gsk.com/en-us/media/press-releases/gsk-impact-awards-for-greater-philadelphia/ 2025-06-19T15:47:08.293Z https://us.gsk.com/en-us/media/press-releases/gsk-honors-triangle-nonprofits-making-a-positive-impact-on-health-outcomes-in-nc/ 2025-06-19T15:47:06.89Z https://us.gsk.com/en-us/media/press-releases/gsk-honors-triangle-nonprofits-making-a-positive-impact-on-health-outcomes/ 2025-06-19T15:47:04.707Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-fluarix-quadrivalent-influenza-vaccine-for-persons-6-months-and-older/ 2025-06-19T15:47:03.08Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus-1/ 2025-06-19T15:47:01.933Z https://us.gsk.com/en-us/media/press-releases/fda-approves-expanded-use-of-gsk-hib-vaccine-from-booster-dose-to-full-series/ 2025-09-08T19:57:54.487Z https://us.gsk.com/en-us/media/press-releases/gsk-triangle-community-foundation-issue-call-for-applications-for-gsk-impact-awards-totaling-400-000/ 2025-06-19T15:46:59.187Z https://us.gsk.com/en-us/media/press-releases/gsk-united-way-of-greater-philadelphia-and-southern-new-jersey-issue-call-for-applications-for-20th-anniversary-gsk-impact-awards-totaling-400-000/ 2025-06-19T15:46:58.107Z https://us.gsk.com/en-us/media/press-releases/gsk-science-in-the-summer-expands-to-20-national-locations-for-30th-anniversary/ 2025-06-19T15:46:57.003Z https://us.gsk.com/en-us/media/press-releases/1-million-gsk-impact-grant-awarded-to-build-healthy-futures-for-young-people-aging-out-of-foster-care-in-the-triangle/ 2025-06-19T15:46:56.103Z https://us.gsk.com/en-us/media/press-releases/free-gsk-science-in-the-summer-classes-return-to-philadelphia-for-the-30th-year/ 2025-06-19T15:46:54.967Z https://us.gsk.com/en-us/media/press-releases/gsk-uncovers-the-state-of-uncontrolled-asthma-in-america/ 2025-06-19T15:46:53.987Z https://us.gsk.com/en-us/media/press-releases/update-on-gsks-response-to-the-zika-virus-disease-outbreak/ 2025-09-08T19:57:49.25Z https://us.gsk.com/en-us/media/press-releases/gsk-ships-2016-17-seasonal-influenza-vaccines-for-us-market/ 2025-06-19T15:46:51.187Z https://us.gsk.com/en-us/media/press-releases/fda-approves-flonase-sensimist-allergy-relief/ 2025-06-19T15:46:49.637Z https://us.gsk.com/en-us/media/press-releases/gsk-unveils-campaign-to-help-prevent-meningitis/ 2025-06-19T15:46:48.113Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-200-000-grant-to-east-durham-children-s-initiative/ 2025-06-19T15:46:45.677Z https://us.gsk.com/en-us/media/press-releases/gsk-celebrates-20-years-of-a-healthy-and-happy-philadelphia/ 2025-06-19T15:46:43.997Z https://us.gsk.com/en-us/media/press-releases/gsk-supports-a-healthy-and-happy-triangle-with-400-000/ 2025-06-19T15:46:43.037Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older-1/ 2025-06-19T15:46:41.84Z https://us.gsk.com/en-us/media/press-releases/gsk-reaches-agreement-to-acquire-tesaro-an-oncology-focused-biopharmaceutical-company/ 2025-09-08T19:57:43.53Z https://us.gsk.com/en-us/media/press-releases/gsk-to-divest-horlicks-and-other-consumer-healthcare-nutrition-products-to-unilever/ 2025-06-23T15:31:38.22Z https://us.gsk.com/en-us/media/press-releases/gsk-employees-celebrate-giving-tuesday-with-awards-to-local-nonprofits/ 2025-06-19T15:46:37.66Z https://us.gsk.com/en-us/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval/ 2025-09-08T19:57:37.267Z https://us.gsk.com/en-us/media/press-releases/access-to-medicine-index-2018-media-statement/ 2025-09-08T19:57:31.763Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-results-of-indirect-treatment-comparisons-of-nucala-to-benralizumab-and-reslizumab-for-severe-eosinophilic-asthma-1/ 2025-06-19T15:46:34.167Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-1-million-grant-to-protect-children-in-north-carolina-puerto-rico-from-disaster/ 2025-06-19T15:46:33Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-greater-philadelphia-nonprofits-making-a-dynamic-impact-on-health-outcomes/ 2025-06-19T15:46:31.817Z https://us.gsk.com/en-us/media/press-releases/two-positive-phase-iii-studies-of-tafenoquine-for-the-radical-cure-of-plasmodium-vivax-malaria-published-in-the-new-england-journal-of-medicine/ 2025-06-19T15:46:29.947Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-succession-plan-to-appoint-new-chairman/ 2025-09-08T19:57:27.24Z https://us.gsk.com/en-us/media/press-releases/gsk-completes-acquisition-of-tesaro-an-oncology-focused-biopharmaceutical-company/ 2025-09-08T19:57:22.543Z https://us.gsk.com/en-us/media/press-releases/gsk-and-merck-kgaa-darmstadt-germany-announce-global-alliance-to-jointly-develop-and-commercialize-m7824-a-novel-immunotherapy-with-potential-in-multiple-difficult-to-treat-cancers/ 2025-09-08T19:57:16.017Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-sales-earnings-and-cash-flow-growth-in-2018/ 2025-06-19T15:46:25.08Z https://us.gsk.com/en-us/media/press-releases/glaxosmithkline-plc-and-pfizer-inc-to-form-new-world-leading-consumer-healthcare-joint-venture/ 2025-06-19T15:46:23.567Z https://us.gsk.com/en-us/media/press-releases/gsk-science-in-the-summer-unveils-2019-curriculum/ 2025-06-24T08:57:16.54Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-a-positive-chmp-opinion-for-intravenous-zanamivir-for-the-treatment-of-complicated-influenza/ 2025-09-08T19:57:10.743Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-two-pivotal-phase-iii-studies/ 2025-09-08T19:57:05.533Z https://us.gsk.com/en-us/media/press-releases/gsk-sponsors-gsk-science-in-the-summer-with-morehead-planetarium/ 2025-06-24T09:00:12.527Z https://us.gsk.com/en-us/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/ 2025-06-24T09:02:14.053Z https://us.gsk.com/en-us/media/press-releases/middle-school-teachers-get-hands-on-experience-in-stem-careers/ 2025-06-19T15:46:12.163Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-further-positive-data-from-dreamm-1-study-of-anti-bcma-antibody-drug-conjugate-in-patients-with-relapsedrefracatory-multiple-myeloma/ 2025-09-08T19:57:00.253Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/ 2025-09-08T19:56:53.543Z https://us.gsk.com/en-us/media/press-releases/eighty-philadelphia-teachers-to-attend-empowering-stem-on-monday-april-8th/ 2025-06-24T09:04:46.727Z https://us.gsk.com/en-us/media/press-releases/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naive-hiv-1-adults/ 2025-09-08T19:56:46.987Z https://us.gsk.com/en-us/media/press-releases/gsk-invests-100-million-to-expand-long-term-vaccine-manufacturing-capabilities-in-hamilton-mt/ 2025-06-24T09:06:22.707Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-dovato-dolutegravirlamivudine-as-a-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-infection/ 2025-06-24T09:08:35.003Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-us-approval-of-benlysta-for-intravenous-use-in-children-with-lupus-aged-five-years-and-above/ 2025-06-24T09:12:56.347Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-the-first-monthly-injectable-two-drug-regimen-of-cabotegravir-and-rilpivirine-for-treatment-of-hiv/ 2025-06-19T15:45:57.63Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-sales-of-77-billion-plus6-aer-plus5-cer/ 2025-06-23T15:02:19.803Z https://us.gsk.com/en-us/media/press-releases/phase-iii-captain-study-of-trelegy-ellipta-in-patients-with-asthma-meets-primary-endpoint/ 2025-06-24T09:17:16.343Z https://us.gsk.com/en-us/media/press-releases/gsk-science-in-the-summer-aims-to-inspire-youth-with-stem-learning-through-the-science-of-me/ 2025-06-24T09:18:52.233Z https://us.gsk.com/en-us/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/ 2025-06-24T09:25:58.607Z https://us.gsk.com/en-us/media/press-releases/gsk-changes-sales-representative-incentive-program/ 2025-09-08T19:56:42.007Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over/ 2025-09-08T19:56:37.027Z https://us.gsk.com/en-us/media/press-releases/save-the-children-announces-15-million-grant-from-gsk-to-enhance-disaster-relief/ 2025-09-08T19:56:32.24Z https://us.gsk.com/en-us/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-new-self-administration-options/ 2025-09-08T19:56:26.997Z https://us.gsk.com/en-us/media/press-releases/nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options/ 2025-09-08T19:56:21.993Z https://us.gsk.com/en-us/media/press-releases/gsk-joins-forces-with-the-university-of-california-to-advance-genomic-research-and-improve-drug-discovery/ 2025-06-23T14:55:27.437Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-phase-iii-start-for-its-anti-gm-csf-antibody-otilimab-in-patients-with-rheumatoid-arthritis-ra/ 2025-06-24T09:30:21.907Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-start-of-first-ever-study-to-identify-and-evaluate-approaches-to-implementing-its-once-monthly-injectable-hiv-treatment-in-clinical-practice/ 2025-06-23T14:47:04.397Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint-demonstrating-the-ability-to-control-hiv-1-with-the-2-drug-regimen-dovato-dolutegravir-plus-lamivudine/ 2025-06-24T09:32:52.237Z https://us.gsk.com/en-us/media/press-releases/ias-2019-viiv-healthcare-showcasing-innovation-in-hiv-science/ 2025-06-23T14:42:34.99Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-prima-study-of-zejula-niraparib-for-patients-with-ovarian-cancer-in-the-first-line-maintenance-setting/ 2025-06-23T14:41:13.383Z https://us.gsk.com/en-us/media/press-releases/gsk-ships-2019-20-seasonal-influenza-vaccines-for-us-market/ 2025-06-23T13:28:22.313Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-96-week-data-from-phase-iii-study-of-investigational-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv-at-ias-2019/ 2025-06-23T13:21:52.547Z https://us.gsk.com/en-us/media/press-releases/glaxosmithkline-plc-appoints-jonathan-symonds-as-non-executive-chairman-of-the-board-of-directors/ 2025-09-08T19:56:17.26Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-sales-and-earnings-growth-in-q2-2019/ 2025-09-08T19:56:12.49Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-gemini-1-2-studies-through-week-96-showing-2-drug-regimen-of-dolutegravir-plus-lamivudine-continues-to-demonstrate-high-efficacy-rates/ 2025-06-23T13:10:43.53Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-positive-week-48-results-in-first-study-to-evaluate-treatment-switch-from-taf-containing-regimen/ 2025-06-23T13:07:44.263Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-investigational-cabotegravir-to-be-used-in-combination-with-rilpivirine/ 2025-06-23T13:05:00.24Z https://us.gsk.com/en-us/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/ 2025-09-08T19:56:07.743Z https://us.gsk.com/en-us/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/ 2025-06-19T15:45:18.473Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-leadership-changes-in-the-us/ 2025-06-19T15:45:16.637Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/ 2025-06-23T13:02:12.513Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-headline-results-from-the-pivotal-dreamm-2-study-for-multiple-myeloma/ 2025-06-24T09:34:41.963Z https://us.gsk.com/en-us/media/press-releases/gsk-to-present-data-from-its-innovative-oncology-portfolio-at-esmo-congress-2019/ 2025-09-08T19:56:03.29Z https://us.gsk.com/en-us/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/ 2025-09-08T19:55:59.49Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-positive-chmp-opinion-for-intravenous-benlysta-in-children-with-lupus-aged-five-years-and-above/ 2025-09-08T19:55:55.78Z https://us.gsk.com/en-us/media/press-releases/real-world-effectiveness-evidence-among-gsk-data-presented-at-ers-2019/ 2025-06-19T15:45:10.733Z https://us.gsk.com/en-us/media/press-releases/gsk-invests-120-million-in-next-generation-us-biopharmaceutical-manufacturing-facility/ 2025-06-19T15:45:10.043Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-new-data-showing-promising-anti-tumour-activity-with-gsk3359609-an-icos-receptor-agonist-in-combination-with-pembrolizumab-in-head-and-neck-squamous-cell-carcinoma-hnscc/ 2025-06-23T11:51:29.627Z https://us.gsk.com/en-us/media/press-releases/phase-3-prima-trial-of-zejula-niraparib-is-the-first-study-to-show-a-parp-inhibitor-significantly-improves-pfs-regardless-of-biomarker-status/ 2025-06-23T11:43:51.123Z https://us.gsk.com/en-us/media/press-releases/idweek-2019-viiv-healthcare-to-present-20-abstracts-from-its-innovative-rd-portfolio-with-focus-on-2-drug-and-long-acting-regimens-and-mental-health-impact-of-hiv/ 2025-06-23T11:29:48.94Z https://us.gsk.com/en-us/media/press-releases/gsk-submits-filing-to-fda-for-trelegy-ellipta-use-in-patients-with-asthma/ 2025-06-23T11:16:42.023Z https://us.gsk.com/en-us/media/press-releases/gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies/ 2025-09-08T19:55:51.77Z https://us.gsk.com/en-us/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ 2025-06-23T11:07:34.42Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-us-food-and-drug-administration-approval-of-additional-indication-for-zejula-niraparib-for-late-line-treatment-for-women-with-recurrent-ovarian-cancer/ 2025-06-19T15:45:01.85Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-new-events-in-the-us-in-lupus-campaign-to-reach-women-of-color/ 2025-06-19T15:44:59.42Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-prestigious-prix-galien-usa-award-for-shingrix/ 2025-06-19T15:44:57.187Z https://us.gsk.com/en-us/media/press-releases/gsk-starts-a-phase-iii-clinical-programme-for-a-potential-first-in-class-antibiotic-gepotidacin/ 2025-06-19T15:44:56.297Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-sales-of-94-billion-plus16-aer-plus11-cer-pro-forma-plus6-cerstar/ 2025-06-23T11:03:10.19Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-triangle-nonprofits-making-a-powerful-impact-on-health-outcomes/ 2025-06-19T15:44:54.04Z https://us.gsk.com/en-us/media/press-releases/gsk-awarding-400-000-to-greater-philadelphia-nonprofits-making-an-impact-on-health-outcomes/ 2025-06-19T15:44:52.207Z https://us.gsk.com/en-us/media/press-releases/gsk-employees-celebrate-givingtuesday-with-190-000-in-awards-to-local-nonprofits/ 2025-06-19T15:44:51.013Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-files-submissions-to-the-fda-and-ema-for-the-first-ever-dispersible-formulation-of-dolutegravir-dtg-for-children-living-with-hiv/ 2025-06-19T15:44:49.857Z https://us.gsk.com/en-us/media/press-releases/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsedrefractory-multiple-myeloma/ 2025-06-19T15:44:48.653Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis/ 2025-06-19T15:44:47.423Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-receives-complete-response-letter-from-us-fda-for-use-of-investigational-cabotegravir-and-rilpivirine-long-acting-regimen-in-the-treatment-of-hiv/ 2025-09-08T19:55:47.793Z https://us.gsk.com/en-us/media/press-releases/deborah-waterhouse-ceo-of-viiv-healthcare-to-join-gsk-corporate-executive-team-cet/ 2025-09-08T19:55:43.487Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-submits-regulatory-application-to-the-european-medicines-agency-for-fostemsavir/ 2025-09-08T19:55:39.24Z https://us.gsk.com/en-us/media/press-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma/ 2025-09-08T19:55:35.24Z https://us.gsk.com/en-us/media/press-releases/gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development/ 2025-09-08T19:55:31.52Z https://us.gsk.com/en-us/media/press-releases/cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus/ 2025-09-08T19:55:26.53Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-2019-sales-of-338-billion-plus10-aer-plus8-cer-pro-forma-plus4-cerstar/ 2025-09-08T19:55:22.293Z https://us.gsk.com/en-us/media/press-releases/fda-approves-gsk-s-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states/ 2025-06-19T15:44:39.603Z https://us.gsk.com/en-us/media/press-releases/us-fda-accepts-gsk-s-snda-application-for-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer/ 2025-06-19T15:44:38.693Z https://us.gsk.com/en-us/media/press-releases/our-contribution-to-the-fight-against-novel-coronavirus-covid-19/ 2025-06-19T15:44:37.61Z https://us.gsk.com/en-us/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/ 2025-09-08T19:55:17.983Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-initiates-study-with-the-university-of-south-carolina-to-evaluate-the-benefits-of-ride-sharing-services-on-improving-access-to-care-for-people-living-with-hiv/ 2025-06-19T15:44:35.767Z https://us.gsk.com/en-us/media/press-releases/fda-approves-gsk-s-advil-dual-action-with-acetaminophen-for-over-the-counter-use-in-the-united-states/ 2025-06-19T15:44:35Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-and-unc-chapel-hill-announce-five-year-renewal-of-innovative-hiv-cure-partnership/ 2025-09-08T19:55:13.493Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/ 2025-09-08T19:55:09.24Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-long-term-data-from-phase-iii-study-demonstrating-efficacy-and-safety-of-cabotegravir-and-rilpivirine/ 2025-09-08T19:55:04.237Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-first-global-regulatory-approval-of-cabenuva-the-first-complete-long-acting-regimen-for-the-treatment-of-hiv/ 2025-09-08T19:54:59.733Z https://us.gsk.com/en-us/media/press-releases/gsk-appoints-charles-bancroft-to-the-board-as-a-non-executive-director/ 2025-09-08T19:54:55.487Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/ 2025-09-08T19:54:52.49Z https://us.gsk.com/en-us/media/press-releases/voltaren-arthritis-pain-and-the-arthritis-foundation-announce-multi-year-partnership-to-help-people-living-with-osteoarthritis/ 2025-06-19T15:44:26.753Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/ 2025-09-08T19:54:48.26Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-new-data-from-the-garnet-study-demonstrating-potential-of-dostarlimab-to-treat-a-subset-of-women-with-recurrent-or-advanced-endometrial-cancer/ 2025-06-19T15:44:24.903Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-strong-q1-sales-91-billion-plus19-aer-plus19-cer-proforma-plus10-cerstar/ 2025-06-20T13:56:36.427Z https://us.gsk.com/en-us/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status/ 2025-09-08T19:54:44.74Z https://us.gsk.com/en-us/media/press-releases/gsk-highlights-scientific-innovation-and-advances-in-its-growing-oncology-portfolio-at-asco-2020/ 2025-09-08T19:54:41.527Z https://us.gsk.com/en-us/media/press-releases/gsk-partners-with-samsung-biologics-to-secure-additional-manufacturing-capacity-for-innovative-biopharmaceutical-portfolio/ 2025-09-08T19:54:38.743Z https://us.gsk.com/en-us/media/press-releases/dreamm-2-and-dreamm-6-data-at-asco/ 2025-09-08T19:54:34.76Z https://us.gsk.com/en-us/media/press-releases/fda-grants-priority-review-of-nucala-for-patients-with-hypereosinophilic-syndrome-hes/ 2025-09-08T19:54:32Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-intention-to-produce-1-billion-doses-of-pandemic-vaccine-adjuvant/ 2025-09-08T19:54:27.75Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-new-data-presentations-from-the-dreamm-programme/ 2025-09-08T19:54:23.24Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-the-first-ever-dispersible-tablet-formulation-of-dolutegravir/ 2025-09-08T19:54:19.27Z https://us.gsk.com/en-us/media/press-releases/ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-precision-medicine-oncology/ 2025-09-08T19:54:15.047Z https://us.gsk.com/en-us/media/press-releases/gsk-consumer-healthcare-teams-up-with-paula-abdul-for-the-launch-of-voltaren-arthritis-pain-gel/ 2025-06-19T15:44:14.003Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-proposed-unregistered-offering-of-senior-notes-exchangeable-into-theravance-biopharma-ordinary-shares/ 2025-09-08T19:54:10.733Z https://us.gsk.com/en-us/media/press-releases/gsk-prices-280-336-000-senior-notes-due-2023-exchangeable-into-theravance-biopharma-ordinary-shares/ 2025-09-08T19:54:04.497Z https://us.gsk.com/en-us/media/press-releases/gsk-science-in-the-summer-returns-virtually-for-summer-2020-in-partnership-with-the-franklin-institute/ 2025-06-19T15:44:11.917Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-fda-advisory-committee-meeting-to-review-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsedrefractory-multiple-myeloma/ 2025-09-08T19:54:00.01Z https://us.gsk.com/en-us/media/press-releases/gsk-covid-19-vaccine-development-collaboration-with-clover-biopharmaceuticals-begins-clinical-trials/ 2025-09-08T19:53:55.987Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-first-regulatory-approval-for-duvroq-daprodustat-in-japan-for-patients-with-anaemia-due-to-chronic-kidney-disease/ 2025-09-08T19:53:51.233Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-at-aids-2020-virtual/ 2025-09-08T19:53:46.983Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/ 2025-06-19T15:44:08.267Z https://us.gsk.com/en-us/media/press-releases/gsk-consumer-healthcare-selects-publicis-production-and-tag-to-reinvent-end-to-end-marketing-ecosystem/ 2025-06-19T15:44:07.483Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-implementation-research-study-on-how-best-to-integrate-an-investigational-once-monthly-injectable-hiv-treatment-in-us-healthcare-practices/ 2025-09-08T19:53:42.743Z https://us.gsk.com/en-us/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/ 2025-09-08T19:53:38.493Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-superior-efficacy-of-investigational-long-acting-injectable-formulation-of-cabotegravir-dosed-every-two-months-over-daily-oral-prep/ 2025-09-08T19:53:33.49Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-fda-advisory-committee-votes-in-favour-of-positive-benefitrisk-profile-for-belantamab-mafodotin-for-patients-with-relapsedrefractory-multiple-myeloma/ 2025-09-08T19:53:28.493Z https://us.gsk.com/en-us/media/press-releases/gsk-and-curevac-announce-strategic-mrna-technology-collaboration/ 2025-09-08T19:53:24.013Z https://us.gsk.com/en-us/media/press-releases/gsk-begins-shipping-record-number-of-its-influenza-vaccine-doses-for-2020-21-season-for-us-market/ 2025-06-19T15:44:02.243Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine/ 2025-09-08T19:53:19.773Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-q2-sales-of-76-billion-2-aer-3-cer-pro-forma-10-cerstar/ 2025-06-23T11:10:45.2Z https://us.gsk.com/en-us/media/press-releases/gsk-to-share-evidence-supporting-a-personalised-approach-to-asthma-treatment-at-ats-2020-virtual/ 2025-06-19T15:43:58.267Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/ 2025-09-08T19:53:15.747Z https://us.gsk.com/en-us/media/press-releases/gsk-launches-national-public-awareness-campaign-to-reverse-steep-decline-in-already-low-immunization-rates-for-adults/ 2025-06-19T15:43:56.62Z https://us.gsk.com/en-us/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/ 2025-06-19T15:43:55.653Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-10m-program-to-advance-black-people-latinx-people-women-in-stem/ 2025-06-19T15:43:54.81Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-first-participant-vaccinated-in-phase-3-clinical-trials-of-its-5-in-1-meningitis-abcwy-vaccine-candidate/ 2025-09-08T19:53:11.987Z https://us.gsk.com/en-us/media/press-releases/low-adult-immunization-rates-decline-further-due-to-pandemic/ 2025-06-19T15:43:52.127Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/ 2025-09-08T19:53:08.237Z https://us.gsk.com/en-us/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/ 2025-09-08T19:53:03.983Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/ 2025-09-08T19:52:59.237Z https://us.gsk.com/en-us/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/ 2025-06-19T15:43:46.877Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/ 2025-09-08T19:52:54.983Z https://us.gsk.com/en-us/media/press-releases/fda-approves-nucala-as-the-first-and-only-biologic-treatment-for-hypereosinophilic-syndrome-hes/ 2025-06-19T15:43:43.66Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-start-of-implementation-science-study/ 2025-09-08T19:52:49.763Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-dolutegravir-plus-lamivudine-three-year-data-confirming-long-term-viral-suppression/ 2025-06-19T15:43:41.36Z https://us.gsk.com/en-us/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/ 2025-09-08T19:52:46.733Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-long-term-switch-data-for-dovato/ 2025-06-19T15:43:38.933Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-positive-clinical-data-on-maternal-and-older-adults-rsv-candidate-vaccines/ 2025-09-08T19:52:41.51Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-analysis-showing-no-antiretroviral-therapy-interruptions-due-to-covid-19/ 2025-09-08T19:52:37.487Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-continued-positive-findings-from-first-ever-implementation-science-study/ 2025-09-08T19:52:32.987Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-new-findings-from-two-studies-of-its-investigational-long-acting-regimen-of-cabotegravir-and-rilpivirine/ 2025-09-08T19:52:27.497Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-resilient-performance-strong-commercial-execution-and-further-strategic-progress-in-q3/ 2025-09-08T19:52:21.993Z https://us.gsk.com/en-us/media/press-releases/gsk-sets-new-environmental-goals-of-net-zero-impact-on-climate-and-net-positive-impact-on-nature-by-2030/ 2025-09-08T19:52:17.533Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-investigational-injectable-cabotegravir-is-superior-to-oral-standard-of-care-for-hiv-prevention-in-women/ 2025-09-08T19:52:13.257Z https://us.gsk.com/en-us/media/press-releases/gsk-highlights-progress-from-the-blenrep-belantamab-mafodotin-blmf-development-programme-in-multiple-myeloma-at-ash-annual-meeting/ 2025-06-19T15:43:31.697Z https://us.gsk.com/en-us/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/ 2025-09-08T19:52:07.003Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe/ 2025-06-19T15:43:28.73Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-phase-2b-data-on-linerixibat-for-the-treatment-of-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc/ 2025-09-08T19:52:00.003Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-triangle-nonprofits-making-a-powerful-impact-on-health-outcomes-now-more-than-ever/ 2025-09-08T19:51:53.793Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-receives-fda-breakthrough-therapy-designation-for-investigational-long-acting-cabotegravir-for-hiv-prevention/ 2025-09-08T19:51:49.237Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-results-of-the-progress-study-demonstrating-that-the-inclusion-of-patient-reported-outcomes-into-clinical-practice-can-improve-hiv-care/ 2025-09-08T19:51:44.983Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-greater-philadelphia-nonprofits-making-a-powerful-impact-on-health-outcomes-now-more-than-ever/ 2025-06-19T15:43:24.673Z https://us.gsk.com/en-us/media/press-releases/gsk-and-mmv-present-positive-data-on-treatment-for-plasmodium-vivax-malaria-in-children-from-6-months-up-to-15-years-of-age/ 2025-09-08T19:51:40.997Z https://us.gsk.com/en-us/media/press-releases/gsk-starts-phase-3-study-of-rsv-maternal-candidate-vaccine/ 2025-09-08T19:51:36.51Z https://us.gsk.com/en-us/media/press-releases/fda-accepts-gsk-s-filing-of-nucala-mepolizumab-for-use-in-chronic-rhinosinusitis-with-nasal-polyps/ 2025-09-08T19:51:32.267Z https://us.gsk.com/en-us/media/press-releases/gsk-consumer-healthcare-partners-with-direct-relief-to-donate-1-million-to-support-frontline-healthcare-workers/ 2025-06-19T15:43:21.63Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/ 2025-09-08T19:51:24.99Z https://us.gsk.com/en-us/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial/ 2025-09-08T19:51:27.497Z https://us.gsk.com/en-us/media/press-releases/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us/ 2025-09-08T19:51:20.737Z https://us.gsk.com/en-us/media/press-releases/vir-biotechnology-and-gsk-announce-nhs-supported-agile-study-to-evaluate-vir-7832-in-the-early-treatment-of-covid-19/ 2025-09-08T19:51:15.253Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-positive-efficacy-data-of-dostarlimab-in-mismatch-repair-deficient-dmmr-solid-cancers-at-asco-gastrointestinal-cancers-symposium/ 2025-09-08T19:51:10.25Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/ 2025-06-19T15:43:16.323Z https://us.gsk.com/en-us/media/press-releases/gsk-ranks-1st-in-the-2021-access-to-medicine-index-with-leading-rd-pipeline-for-priority-diseases/ 2025-09-08T19:51:06.487Z https://us.gsk.com/en-us/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial/ 2025-06-19T15:43:14.377Z https://us.gsk.com/en-us/media/press-releases/gsk-path-and-bharat-biotech-sign-product-transfer-agreement-to-help-ensure-long-term-supply-of-rts-sas01e-malaria-vaccine/ 2025-09-08T19:51:00.997Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-fy-2020-reported-sales-of-34-billion/ 2025-09-08T19:50:55.787Z https://us.gsk.com/en-us/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/ 2025-09-08T19:50:50.51Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-over-1m-for-local-nonprofits-to-increase-equity-in-stem-education/ 2025-06-19T15:43:10.813Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-gender-and-diversity-aspirational-targets-to-increase-representation-at-senior-levels/ 2025-09-08T19:50:44.49Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-expand-coronavirus-collaboration-to-advance-new-therapeutics-for-influenza/ 2025-09-08T19:50:39.01Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-initiate-new-phase-2-study-of-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate/ 2025-09-08T19:50:34.023Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-submits-supplemental-new-drug-application-to-us-fda-for-expanded-use-of-cabenuva-cabotegravir-rilpivirine-as-an-hiv-treatment-for-use-every-2-months/ 2025-06-19T15:43:07.727Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-otilimab-data-for-treatment-of-covid-19/ 2025-09-08T19:50:29.233Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-alongside-pipeline-advances-at-croi-2021/ 2025-09-08T19:50:24.77Z https://us.gsk.com/en-us/media/press-releases/vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/ 2025-09-08T19:50:20.24Z https://us.gsk.com/en-us/media/press-releases/gsk-makes-landmark-pricing-agreement-for-rotavirus-vaccine-rotarix-for-use-with-children-living-in-humanitarian-crises/ 2025-09-08T19:50:15.527Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-data-for-long-acting-cabotegravir-and-rilpivirine-for-the-treatment-of-hiv-showing-continued-virologic-suppression-to-96-weeks/ 2025-06-19T15:43:03.607Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/ 2025-09-08T19:50:11.547Z https://us.gsk.com/en-us/media/press-releases/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19/ 2025-06-19T15:43:01.643Z https://us.gsk.com/en-us/media/press-releases/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/ 2025-09-08T19:50:06.77Z https://us.gsk.com/en-us/media/press-releases/gsk-starts-the-first-phase-3-study-with-a-long-acting-anti-il-5-treatment-for-patients-with-severe-asthma/ 2025-09-08T19:50:02.237Z https://us.gsk.com/en-us/media/press-releases/gsk-to-highlight-scientific-research-in-ovarian-and-endometrial-cancer-at-sgo-2021-annual-meeting-on-women-s-cancer/ 2025-06-19T15:42:58.047Z https://us.gsk.com/en-us/media/press-releases/half-of-parents-surveyed-either-cancelled-or-delayed-their-child-s-scheduled-meningitis-vaccination-during-the-covid-19-pandemic-gsk-survey-shows-1/ 2025-06-19T15:42:57.187Z https://us.gsk.com/en-us/media/press-releases/moncef-slaoui-departs-galvani-bioelectronics-board-of-directors/ 2025-09-08T19:49:57.76Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-submission-of-emergency-use-authorization-request-to-fda-for-vir-7831-for-the-early-treatment-of-covid-19/ 2025-09-08T19:49:54.047Z https://us.gsk.com/en-us/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19/ 2025-09-08T19:49:49.013Z https://us.gsk.com/en-us/media/press-releases/gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist/ 2025-09-08T19:49:43.04Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-ema-review-of-dual-action-monoclonal-antibody-vir-7831-for-the-early-treatment-of-covid-19/ 2025-06-19T15:42:53.35Z https://us.gsk.com/en-us/media/press-releases/advil-to-reduce-plastic-in-over-80-million-bottles-by-20-with-new-sustainable-plastic-technology/ 2025-06-19T15:42:52.51Z https://us.gsk.com/en-us/media/press-releases/fda-grants-accelerated-approval-for-gsk-s-jemperli-dostarlimab-gxly-for-women-with-recurrent-or-advanced-dmmr-endometrial-cancer/ 2025-06-19T15:42:51.717Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-q1-sales-of-74-billion-18-aer-15-cer/ 2025-09-08T19:49:38.49Z https://us.gsk.com/en-us/media/press-releases/gsk-students-take-on-the-role-of-engineers-during-gsk-science-in-the-summer-in-partnership-with-the-franklin-institute/ 2025-06-19T15:42:49.76Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-initiates-rolling-submission-of-new-drug-application-with-us-fda-for-long-acting-cabotegravir-for-prevention-of-hiv/ 2025-06-19T15:42:48.77Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-the-start-of-the-ema-rolling-review-of-vir-7831-sotrovimab-for-the-early-treatment-of-covid-19/ 2025-09-08T19:49:32.5Z https://us.gsk.com/en-us/media/press-releases/gsk-consumer-healthcare-commits-to-make-over-a-billion-toothpaste-tubes-recyclable-by-2025-as-part-of-its-ongoing-sustainability-journey/ 2025-09-08T19:49:25.49Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial/ 2025-09-08T19:49:19.767Z https://us.gsk.com/en-us/media/press-releases/medicago-and-gsk-announce-positive-interim-phase-2-results-for-adjuvanted-covid-19-vaccine-candidate/ 2025-09-08T19:49:15.257Z https://us.gsk.com/en-us/media/press-releases/gsk-announced-as-a-principal-partner-of-cop26-un-climate-change-conference/ 2025-09-08T19:49:10.5Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/ 2025-06-19T15:42:41.54Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-initiate-global-phase-3-clinical-efficacy-study-of-covid-19-vaccine-candidate/ 2025-09-08T19:49:05.237Z https://us.gsk.com/en-us/media/press-releases/gsk-to-showcase-scientific-advances-and-progress-in-oncology-at-asco-and-eha/ 2025-06-19T15:42:39.493Z https://us.gsk.com/en-us/media/press-releases/significant-and-sustained-drop-in-teen-and-adult-immunization-rates-during-pandemic-study-shows/ 2025-06-19T15:42:38.547Z https://us.gsk.com/en-us/media/press-releases/gsk-and-iteos-therapeutics-announce-development/ 2025-09-08T19:49:01.49Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab/ 2025-09-08T19:48:57.013Z https://us.gsk.com/en-us/media/press-releases/new-gsk-to-deliver-step-change-in-growth-and-performance-over-next-ten-years/ 2025-09-08T19:48:51.777Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-drug-delivery-technology-to-enable-development-of-ultra-long-acting-medicines-for-hiv/ 2025-09-08T19:48:47.003Z https://us.gsk.com/en-us/media/press-releases/elliott-advisors-uk-letter-to-gsk/ 2025-09-08T19:48:41.743Z https://us.gsk.com/en-us/media/press-releases/gsk-and-alector-collaboration-in-immuno-neurology/ 2025-09-08T19:48:36.787Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-daprodustat-phase-3-headline-results/ 2025-09-08T19:48:31.497Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-new-data-from-diverse-portfolio-and-pipeline/ 2025-06-19T15:42:30.927Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-study-shows-new-long-acting-hiv-regimen-cabenuva-can-be-successfully-implemented/ 2025-06-19T15:42:29.913Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-data-from-second-dovato-switch-study/ 2025-06-19T15:42:28.617Z https://us.gsk.com/en-us/media/press-releases/gsk-begins-shipping-another-record-supply-of-influenza-vaccine-for-2021-22-season-in-us/ 2025-06-19T15:42:27.443Z https://us.gsk.com/en-us/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults/ 2025-09-08T19:48:27.25Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-strong-q2-sales-of-81-billion-plus6-aer-plus15-cer/ 2025-09-08T19:48:21.99Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-fda-approval-for-nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ 2025-06-19T15:42:23.543Z https://us.gsk.com/en-us/media/press-releases/gsk-files-for-licensure-of-mmr-vaccine-in-the-us/ 2025-06-19T15:42:22.777Z https://us.gsk.com/en-us/media/press-releases/second-generation-mrna-covid-19-vaccine-candidate/ 2025-09-08T19:48:13.273Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumors/ 2025-09-08T19:48:08.243Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-ask2bsure-public-health-awareness-campaign-for-meningitis-b-vaccination/ 2025-06-19T15:42:20.55Z https://us.gsk.com/en-us/media/press-releases/sk-bioscience-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/ 2025-09-08T19:48:03.493Z https://us.gsk.com/en-us/media/press-releases/gsk-to-highlight-continued-progress-in-oncology-pipeline-and-portfolio-with-data-presented-at-esmo/ 2025-06-19T15:42:19.05Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-major-renewable-energy-investment-and-low-carbon-inhaler-programme-alongside-life-sciences-sector-race-to-zero-breakthrough-at-nyc-climate-week/ 2025-09-08T19:47:58.02Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-key-data-that-provides-further-support-for-the-use-of-2-drug-regimens/ 2025-06-19T15:42:17.47Z https://us.gsk.com/en-us/media/press-releases/changing-attitudes-to-vaccination-after-the-covid-19-pandemic/ 2025-06-19T15:42:16.5Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-exclusive-license-agreement-with-shionogi-to-develop-third-generation-hiv-integrase-inhibitor-with-potential-for-ultra-long-acting-dosing-intervals/ 2025-06-19T15:42:15.58Z https://us.gsk.com/en-us/media/press-releases/fda-grants-priority-review-to-viiv-healthcare-s-new-drug-application-for-cabotegravir-long-acting-for-prevention-of-hiv/ 2025-09-08T19:47:53.49Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-submits-fda-application-for-first-dispersible-single-tablet-regimen-containing-dolutegravir-dtg-for-children-living-with-hiv/ 2025-06-19T15:42:13.57Z https://us.gsk.com/en-us/media/press-releases/gsk-to-showcase-significant-scientific-advances-in-renal-care-at-the-american-society-of-nephrology-kidney-week-2021/ 2025-06-19T15:42:12.403Z https://us.gsk.com/en-us/media/press-releases/less-talk-more-action-new-report-sponsored-by-viiv-healthcare-provides-roadmap-to-achieve-health-equity-by-2040/ 2025-09-08T19:47:49.037Z https://us.gsk.com/en-us/media/press-releases/votes-unanimously-to-recommend-shingrix-for-immunocompromised-adults-aged-19-and-up/ 2025-06-19T15:42:10.397Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-strong-q3-sales-of-91-billion-plus5-aer-plus10-cer/ 2025-09-08T19:47:44.543Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-positive-interim-data-showing-vocabria-cabotegravir-and-rekambys-rilpivirine-can-be-implemented-successfully-in-a-variety-of-european-healthcare-settings/ 2025-06-19T15:42:07.733Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-phase-iii-efficacy-and-safety-data-for-daprodustat-in-patients-with-anaemia-due-to-chronic-kidney-disease/ 2025-06-19T15:42:06.407Z https://us.gsk.com/en-us/media/press-releases/primary-endpoint-met-in-comet-tail-phase-iii-trial-evaluating-intramuscular-administration-of-sotrovimab-for-early-treatment-of-covid-19/ 2025-09-08T19:47:39.763Z https://us.gsk.com/en-us/media/press-releases/gsk-showcases-progress-from-the-dreamm-clinical-trial-program-in-multiple-myeloma-at-the-2021-ash-annual-meeting/ 2025-06-19T15:42:02.053Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreements-to-purchase-sotrovimab-a-covid-19-treatment/ 2025-06-19T15:41:59.403Z https://us.gsk.com/en-us/media/press-releases/gsk-unveils-target-the-future/ 2025-09-08T19:47:35.503Z https://us.gsk.com/en-us/media/press-releases/gsk-celebrates-25th-impact-awards/ 2025-09-08T19:47:31.233Z https://us.gsk.com/en-us/media/press-releases/preclinical-data-demonstrate-sotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant/ 2025-06-19T15:41:54.667Z https://us.gsk.com/en-us/media/press-releases/sotrovimab-retains-activity/ 2025-06-19T15:41:53.457Z https://us.gsk.com/en-us/media/press-releases/medicago-and-gsk-announce-positive-phase-3-efficacy-and-safety-results/ 2025-09-08T19:47:26.77Z https://us.gsk.com/en-us/media/press-releases/new-survey-reveals-majority-of-severe-eosinophilic-asthma-patients/ 2025-09-08T19:47:21.487Z https://us.gsk.com/en-us/media/press-releases/new-data-presented-at-ash-2021-highlight-potential-of-blenrep-belantamab-mafodotin-blmf-in-combination-with-standard-of-care-therapies-in-earlier-lines-of-multiple-myeloma-treatment/ 2025-06-19T15:41:48.887Z https://us.gsk.com/en-us/media/press-releases/gsk-and-sanofi-announce-positive-preliminary-booster-data-for-their-covid-19-vaccine-candidate/ 2025-09-08T19:47:16.507Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-apretude-cabotegravir-extended-release-injectable-suspension-the-first-and-only-long-acting-injectable-option-for-hiv-prevention/ 2025-06-19T15:41:42.753Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/ 2025-06-19T15:41:40.84Z https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-submit-emergency-use-authorization-application-to-fda-for-intramuscular-administration-of-sotrovimab-for-the-early-treatment-of-covid-19/ 2025-06-19T15:41:39.553Z https://us.gsk.com/en-us/media/press-releases/update-gsk-consumer-healthcare/ 2025-09-08T19:47:11.25Z https://us.gsk.com/en-us/media/press-releases/tony-wood-appointed-chief-scientific-officer-designate-gsk/ 2025-06-19T15:41:37.55Z https://us.gsk.com/en-us/media/press-releases/routine-vaccination-rates-in-teens-and-adults-continue-to-lag/ 2025-09-08T19:47:06.51Z https://us.gsk.com/en-us/media/press-releases/fda-approves-nucala-mepolizumab-40-mg-prefilled-syringe-for-children-with-severe-eosinophilic-asthma/ 2025-06-19T15:41:35.697Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/ 2025-06-19T15:41:34.853Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/ 2025-09-08T19:47:01.29Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-new-long-term-findings-from-its-innovative-2-drug-and-long-acting-hiv-medicines-portfolio-at-croi-2022/ 2025-06-19T15:41:32.16Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/ 2025-06-20T13:29:11.387Z https://us.gsk.com/en-us/media/press-releases/sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/ 2025-06-24T15:02:41.077Z https://us.gsk.com/en-us/media/press-releases/medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz/ 2025-09-08T19:46:55.997Z https://us.gsk.com/en-us/media/press-releases/gsk-to-demonstrate-its-commitment-to-improving-outcomes-for-patients-with-gynecologic-cancer-at-the-2022-sgo-annual-meeting/ 2025-06-19T15:41:26.713Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-label-update-for-its-long-acting-hiv-treatment-cabenuva-cabotegravir-rilpivirine-to-be-initiated-with-or-without-an-oral-lead-in-period/ 2025-06-19T15:41:26.1Z https://us.gsk.com/en-us/media/press-releases/us-food-and-drug-administration-revises-emergency-use-authorization-for-sotrovimab-due-to-omicron-ba2-subvariant/ 2025-06-19T15:41:25.55Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-for-virologically-suppressed-adolescents-living-with-hiv-who-are-12-years-of-age-or-older-and-weigh-at-least-35-kg/ 2025-06-19T15:41:24.843Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv/ 2025-06-19T15:41:24.203Z https://us.gsk.com/en-us/media/press-releases/new-large-scale-observational-study-shows-covid-19-could-create-vulnerability-to-shingles-for-people-age-50plus/ 2025-06-19T15:41:23.587Z https://us.gsk.com/en-us/media/press-releases/gsk-selects-target-the-future-grant-recipient-in-innovation-challenge-supporting-multiple-myeloma-community/ 2025-06-19T15:41:23.023Z https://us.gsk.com/en-us/media/press-releases/sanofi-gsk-first-to-report-a-successful-efficacy-study-against-omicron-with-covid-19-beta-containing-vaccine/ 2025-10-07T08:23:46.56Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-its-respiratory-syncytial-virus/ 2025-06-19T15:41:22.04Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-us-fda-approval-of-priorix/ 2025-06-19T15:41:21.543Z https://us.gsk.com/en-us/media/press-releases/gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/ 2025-06-19T15:41:20.94Z https://us.gsk.com/en-us/media/press-releases/gsk-unveils-latest-research-advances-demonstrating-strength-of-its-portfolio-and-pipeline-at-asco-and-eha/ 2025-06-19T15:41:20.37Z https://us.gsk.com/en-us/media/press-releases/local-budding-biologists-explore-the-past-present-and-future/ 2025-06-19T15:41:19.84Z https://us.gsk.com/en-us/media/press-releases/gsk-delivers-strong-q1-2022-sales-of-98-billion/ 2025-06-19T15:41:19.297Z https://us.gsk.com/en-us/media/press-releases/us-food-and-drug-administration-accepts-new-drug-application-for-daprodustat/ 2025-06-19T15:41:18.653Z https://us.gsk.com/en-us/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/ 2025-06-19T15:41:17.597Z https://us.gsk.com/en-us/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/ 2025-06-19T15:41:16.813Z https://us.gsk.com/en-us/media/press-releases/gsk-prepares-us-for-2022-23-flu-season-with-over-50-million-influenza-vaccine-doses/ 2025-06-19T15:41:16.147Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-us-fda-approval-of-benlysta-belimumab-for-pediatric-patients-with-active-lupus-nephritis/ 2025-06-19T15:41:15.447Z https://us.gsk.com/en-us/media/press-releases/gsk-and-iqvia-launch-vaccine-track-a-data-trend-platform-to-help-improve-adult-vaccination-in-communities-nationwide/ 2025-06-19T15:41:14.973Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation/ 2025-06-19T15:41:14.43Z https://us.gsk.com/en-us/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/ 2025-06-19T15:41:14.04Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-us-litigation/ 2025-06-19T15:41:13.57Z https://us.gsk.com/en-us/media/press-releases/us-fda-accepts-new-drug-application-for-gsk-s-momelotinib-for-the-treatment-of-myelofibrosis/ 2025-06-19T15:41:13.07Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-update-on-us-fda-regulatory-review-of-daprodustat-in-anaemia-of-chronic-kidney-disease/ 2025-06-19T15:41:12.563Z https://us.gsk.com/en-us/media/press-releases/oncologic-drugs-advisory-committee-to-review-zejula-overall-survival-data-from-the-nova-phase-iii-trial-in-recurrent-ovarian-cancer/ 2025-06-19T15:41:12.023Z https://us.gsk.com/en-us/media/press-releases/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections/ 2025-06-19T15:41:11.27Z https://us.gsk.com/en-us/media/press-releases/us-fda-approves-boostrix-for-immunization-during-pregnancy-for-the-prevention-of-whooping-cough-in-newborn-infants/ 2025-06-19T15:41:10.793Z https://us.gsk.com/en-us/media/press-releases/gsk-to-present-updates-on-its-industry-leading-infectious-disease-portfolio-at-idweek-2022/ 2025-06-19T15:41:10.337Z https://us.gsk.com/en-us/media/press-releases/us-fda-approves-menveo-in-a-new-single-vial-presentation-to-help-prevent-disease-caused-by-meningococcal-bacteria-serogroups-a-c-y-and-w/ 2025-06-19T15:41:09.823Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-expanded-collaboration-with-tempus-in-precision-medicine-to-accelerate-rd/ 2025-06-19T15:41:09.31Z https://us.gsk.com/en-us/media/press-releases/gsk-reports-outcome-from-us-fda-advisory-committee-meeting-on-daprodustat-for-anaemia-of-ckd/ 2025-06-19T15:41:08.783Z https://us.gsk.com/en-us/media/press-releases/gsk-s-rsv-oa-vaccine-candidate-granted-priority-review-by-us-fda/ 2025-06-19T15:41:08.227Z https://us.gsk.com/en-us/media/press-releases/fda-approves-new-fully-liquid-presentation-of-rotarix/ 2025-06-19T15:41:07.607Z https://us.gsk.com/en-us/media/press-releases/gsk-provides-an-update-on-blenrep-belantamab-mafodotin-blmf-us-marketing-authorization/ 2025-06-19T15:41:07.053Z https://us.gsk.com/en-us/media/press-releases/new-global-survey-reveals-opportunities-to-address-organ-damage-risk-with-people-living-with-lupus-earlier-in-the-course-of-their-disease/ 2025-06-19T15:41:06.587Z https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-06-19T15:41:05.803Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-litigation/ 2025-06-19T15:41:05.057Z https://us.gsk.com/en-us/media/press-releases/new-data-at-ash-underscore-the-potential-for-durable-clinically-important-responses-with-momelotinib-for-myelofibrosis-patients/ 2025-06-19T15:41:04.533Z https://us.gsk.com/en-us/media/press-releases/benlysta-granted-orphan-drug-designation-by-us-fda-for-the-potential-treatment-of-systemic-sclerosis/ 2025-06-19T15:41:04.06Z https://us.gsk.com/en-us/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anemia-of-chronic-kidney-disease-in-adults-on-dialysis/ 2025-06-19T15:41:03.4Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-results-from-17-year-retrospective-study-on-us-clinical-trial-diversity/ 2025-06-19T15:41:02.84Z https://us.gsk.com/en-us/media/press-releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer/ 2025-06-19T15:41:02.39Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-first-head-to-head-data-for-long-acting-hiv-treatment-cabenuva-against-daily-oral-biktarvy-at-croi-2023/ 2025-06-19T15:41:01.857Z https://us.gsk.com/en-us/media/press-releases/nejm-publication-reinforces-potential-of-gsk-s-respiratory-syncytial-virus-older-adult-vaccine-candidate/ 2025-06-19T15:41:01.39Z https://us.gsk.com/en-us/media/press-releases/us-fda-advisory-committee-votes-to-support-effectiveness-and-safety-of-gsk-s-rsv-older-adult-vaccine-candidate/ 2025-06-19T15:41:00.8Z https://us.gsk.com/en-us/media/press-releases/gsk-and-earvin-magic-johnson-partner-to-raise-awareness-of-risk-of-rsv-in-older-adults/ 2025-06-19T15:41:00.213Z https://us.gsk.com/en-us/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer/ 2025-06-26T13:52:50.943Z https://us.gsk.com/en-us/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-bellus-health/ 2025-06-19T15:40:58.663Z https://us.gsk.com/en-us/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-06-19T15:40:57.913Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-us-fda-file-acceptance-for-jemperli/ 2025-06-19T15:40:57.357Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-the-coimmunity-initiative-to-help-achieve-higher-adult-vaccination-rates-in-the-us/ 2025-06-19T15:40:56.87Z https://us.gsk.com/en-us/media/press-releases/gsk-and-lifetime-release-short-film/ 2025-06-26T11:44:20.927Z https://us.gsk.com/en-us/media/press-releases/gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-rsv-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/ 2025-06-19T15:40:55.863Z https://us.gsk.com/en-us/media/press-releases/cdcp-acip-votes-to-recommend-arexvy/ 2025-06-24T14:01:43.8Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-investigational-vaccine-against-gonorrhoea/ 2025-06-20T13:23:00.593Z https://us.gsk.com/en-us/media/press-releases/gsk-is-first-to-ship-influenza-vaccine-doses-for-the-2023-24-flu-season-in-us/ 2025-06-19T15:40:54.19Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-arexvy-its-respiratory-syncytial-virus-rsv-vaccine-is-now-available-at-all-major-us-retail-pharmacies/ 2025-06-26T11:20:01.053Z https://us.gsk.com/en-us/media/press-releases/gsk-and-earvin-magic-johnson-to-host-community-awareness-events-about-older-adult-risk-for-rsv-at-ymca-locations/ 2025-06-19T15:40:52.56Z https://us.gsk.com/en-us/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anemia/ 2025-06-19T15:40:52.007Z https://us.gsk.com/en-us/media/press-releases/new-data-for-arexvy/ 2025-06-19T15:40:51.37Z https://us.gsk.com/en-us/media/press-releases/gsk-celebrates-2023-impact-award-winners/ 2025-06-19T15:40:50.82Z https://us.gsk.com/en-us/media/press-releases/gsk-and-queer-eyes-thom-filicia-partner-on-blood-cancer-awareness-initiative/ 2025-06-19T15:40:50.13Z https://us.gsk.com/en-us/media/press-releases/new-global-analysis-across-five-cities-shows-inequities-in-adult-immunization-uptake-signaling-need-to-redesign-local-and-national-policy-interventions/ 2025-06-19T15:40:49.55Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-1m-in-coimmunity-initiative-grants-to-support-adult-immunization-and-health-equity/ 2025-06-19T15:40:49.007Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-new-packaging-option-now-available-in-the-us-for-dovato-dolutegravirlamivudine/ 2025-06-19T15:40:48.437Z https://us.gsk.com/en-us/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2025-06-26T10:49:33.237Z https://us.gsk.com/en-us/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/ 2025-06-19T15:40:47.243Z https://us.gsk.com/en-us/media/press-releases/latitude-phase-iii-interim-trial-data-indicates-cabenuva-has-superior-efficacy-compared-to-daily-therapy/ 2025-06-19T15:40:46.727Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-to-present-data-for-its-next-generation-of-ultra-long-acting-treatments-for-hiv/ 2025-06-19T15:40:46.04Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-presents-phase-i-clinical-trial-findings-of-a-cabotegravir-long-acting-injectable-investigational-formulation-allowing-at-least-four-months-between-doses/ 2025-06-19T15:40:45.43Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-interim-data-at-croi-indicating-superior-efficacy-of-long-acting-injectable-hiv-treatment-cabenuva-compared-to-daily-oral-therapy/ 2025-06-19T15:40:44.733Z https://us.gsk.com/en-us/media/press-releases/gsk-doubles-coimmunity-grant-funding-launches-patient-resources-as-adult-vaccination-rates-begin-to-show-promising-rise/ 2025-06-19T15:40:44.21Z https://us.gsk.com/en-us/media/press-releases/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-gxly-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-06-19T15:40:43.55Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-cap-of-35-per-month-on-us-patient-out-of-pocket-costs-for-its-entire-portfolio-of-asthma-and-copd-inhalers/ 2025-06-19T15:40:42.313Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-dovato-for-adolescents-living-with-hiv/ 2025-06-19T15:40:38.313Z https://us.gsk.com/en-us/media/press-releases/gsks-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda/ 2025-06-19T15:40:36.667Z https://us.gsk.com/en-us/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles/ 2025-06-19T15:40:34.78Z https://us.gsk.com/en-us/media/press-releases/fda-accepts-gsk-application-expanded-indication-of-jemperli-dostarlimab-plus-chemotherapy-include-all-adult-patients-primary-advanced-recurrent-endometrial-cancer/ 2025-06-19T15:40:33.083Z https://us.gsk.com/en-us/media/press-releases/fda-approves-benlysta-belimumab-autoinjector-for-children-with-systemic-lupus-erythematosus/ 2025-06-19T15:40:31.667Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-valadez-and-williams-cases/ 2025-06-19T15:40:30.397Z https://us.gsk.com/en-us/media/press-releases/new-data-at-asco-showcases-the-transformational-potential-of-gsks-oncology-portfolio/ 2025-06-19T15:40:29.007Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-delaware-state-court-daubert-ruling/ 2025-06-19T15:40:27.093Z https://us.gsk.com/en-us/media/press-releases/belantamab-mafodotin-combination-reduced-the-risk-of-disease/ 2025-06-19T15:40:25.823Z https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-trial-continues-to-show-unprecedented-results/ 2025-06-19T15:40:24.29Z https://us.gsk.com/en-us/media/press-releases/gsk-accelerates-oligonucleotide-platform-and-pipeline-medicines-with-acquisition-of-elsie-biotechnologies/ 2025-06-19T15:40:23.1Z https://us.gsk.com/en-us/media/press-releases/us-fda-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2025-06-19T15:40:22.163Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-kasza-case/ 2025-06-19T15:40:21.187Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-gsk-starts-process-for-appeal-of-recent-delaware-daubert-decision/ 2025-06-19T15:40:20.427Z https://us.gsk.com/en-us/media/press-releases/students-nationwide-take-on-the-role-of-space-scientists-during-gsk-science-in-the-summer-in-collaboration-with-the-franklin-institute/ 2025-06-19T15:40:19.593Z https://us.gsk.com/en-us/media/press-releases/statement-us-centers-for-disease-control-and-prevention-s-advisory-committee-on-immunization-practices-updates-recommendations-on-adult-rsv-vaccines-ahead-of-the-next-season/ 2025-06-19T15:40:18.677Z https://us.gsk.com/en-us/media/press-releases/gsk-begins-shipping-influenza-vaccine-doses-for-2024-25-season/ 2025-06-19T15:40:17.397Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-kimbrow-case/ 2025-06-19T15:40:16.29Z https://us.gsk.com/en-us/media/press-releases/gsk-and-flagship-pioneering-partner-to-discover-novel-medicines-and-vaccines/ 2025-06-19T15:40:15.353Z https://us.gsk.com/en-us/media/press-releases/us-fda-expands-jemperli-plus-chemotherapy-approval-to-all-adult-patients/ 2025-06-19T15:40:14.07Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-litigation-joiner-case/ 2025-06-19T15:40:13.32Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-florida-state-court-daubert-ruling-in-wilson-case/ 2025-06-19T15:40:12.783Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-delaware-supreme-court-to-review-superior-court-s-daubert-decision/ 2025-06-19T15:40:12.193Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd/ 2025-07-09T17:53:03.603Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-dixon-case/ 2025-06-19T15:40:10.33Z https://us.gsk.com/en-us/media/press-releases/brooke-shields-partners-with-gsk-to-educate-adults-50-and-older-about-their-shingles-risk/ 2025-06-19T15:40:09.643Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-positive-topline-data-on-co-administration-of-arexvy-and-shingrix/ 2025-06-19T15:40:08.573Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-russell-and-hughes-cases-2/ 2025-06-19T15:40:07.357Z https://us.gsk.com/en-us/media/press-releases/gsk-presents-positive-data-for-arexvy-indicating-protection-over-three-rsv-seasons/ 2025-06-19T15:40:06.707Z https://us.gsk.com/en-us/media/press-releases/statement-zantac-ranitidine-litigation-settlement-agreements-reached/ 2025-06-19T15:40:05.51Z https://us.gsk.com/en-us/media/press-releases/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease-portfolio-at-idweek-2024/ 2025-06-19T15:40:04.443Z https://us.gsk.com/en-us/media/press-releases/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/ 2025-06-19T15:40:03.443Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude/ 2025-06-19T15:40:02.273Z https://us.gsk.com/en-us/media/press-releases/new-data-for-arexvy-gsk-s-respiratory-syncytial-virus-vaccine-show-potential-to-help-protect-a-broader-group-of-adults/ 2025-06-19T15:40:00.96Z https://us.gsk.com/en-us/media/press-releases/gsk-invests-up-to-800-million-in-pennsylvania-site-largest-manufacturing-investment-in-us/ 2025-06-19T15:39:59.253Z https://us.gsk.com/en-us/media/press-releases/gsk-celebrates-2024-impact-award-winners/ 2025-06-19T15:39:58.483Z https://us.gsk.com/en-us/media/press-releases/belantamab-mafodotin-shows-survival-benefit-in-dreamm-7-phase-iii-trial/ 2025-06-19T15:39:57.61Z https://us.gsk.com/en-us/media/press-releases/belantamab-mafodotin-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-06-19T15:39:56.42Z https://us.gsk.com/en-us/media/press-releases/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd/ 2025-06-19T15:39:55.51Z https://us.gsk.com/en-us/media/press-releases/belantamab-mafodotin-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse/ 2025-06-19T15:39:54.59Z https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/ 2025-06-19T15:39:52.507Z https://us.gsk.com/en-us/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/ 2025-06-19T15:39:50.337Z https://us.gsk.com/en-us/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-us-fda/ 2025-06-19T15:39:48.907Z https://us.gsk.com/en-us/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/ 2025-06-19T15:39:47.797Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-continues-to-deliver-long-acting-injectable-hiv-innovation-at-croi-2025/ 2025-06-19T15:39:46.2Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-announces-new-implementation-study-data-showing-zero-cases-of-hiv-with-apretude/ 2025-06-19T15:39:44.19Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025/ 2025-06-19T15:39:43.46Z https://us.gsk.com/en-us/media/press-releases/viiv-healthcare-s-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-suppression-in-long-acting-treatment-of-hiv/ 2025-07-03T14:08:54.357Z https://us.gsk.com/en-us/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-uutis-in-female-adults-and-pediatric-patients-12-years-of-age-and-older/ 2025-06-19T15:39:41.94Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-2m-in-grant-funding-for-programs-supporting-adult-vaccination-commits-additional-2m-for-2025/ 2025-06-19T15:39:40.83Z https://us.gsk.com/en-us/media/press-releases/gsk-s-5-in-1-meningococcal-vaccine-penmenvy-receives-positive-recommendation-from-us-advisory-committee-on-immunization-practices/ 2025-06-19T15:39:39.96Z https://us.gsk.com/en-us/media/press-releases/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices/ 2025-06-19T15:39:38.23Z https://us.gsk.com/en-us/media/press-releases/gsk-and-lifetime-launch-original-movie-to-raise-awareness-about-the-impact-of-meningitis/ 2025-06-19T15:39:36.913Z https://us.gsk.com/en-us/media/press-releases/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/ 2026-02-20T15:11:00.417Z https://us.gsk.com/en-us/media/press-releases/nucala-mepolizumab-approved-by-us-fda-for-use-in-adults-with-chronic-obstructive-pulmonary-disease-copd/ 2025-06-19T15:39:25.563Z https://us.gsk.com/en-us/media/press-releases/gsk-data-at-asco-and-eha-showcase-latest-research-and-innovation-across-the-oncology-portfolio/ 2025-06-19T15:39:23.937Z https://us.gsk.com/en-us/media/press-releases/gsk-invests-450-000-in-stem-education-in-philadelphia-public-schools/ 2025-06-19T15:39:22.167Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-the-linked-by-lupus-optimal-care-initiative-to-help-support-individuals-with-lupus-in-the-us/ 2025-06-19T15:39:21.353Z https://us.gsk.com/en-us/media/press-releases/jemperli-plus-chemotherapy-approved-in-us-for-new-indication/ 2025-06-20T13:13:40.02Z https://us.gsk.com/en-us/media/press-releases/fda-approves-benlysta-belimumab-autoinjector-for-children-with-active-lupus-nephritis/ 2025-06-27T12:10:04.14Z https://us.gsk.com/en-us/media/press-releases/gsk-begins-shipping-influenza-vaccine-doses-for-the-2025-26-flu-season/ 2025-07-11T14:14:20.207Z https://us.gsk.com/en-us/media/press-releases/fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine-arexvy/ 2025-07-14T08:27:14.61Z https://us.gsk.com/en-us/media/press-releases/us-fda-approves-gsk-s-shingrix-in-a-prefilled-syringe-presentation/ 2025-07-17T06:05:17.367Z https://us.gsk.com/en-us/media/press-releases/gsk-provides-update-on-us-fda-advisory-committee-review-of-blenrep-belantamab-mafodotin-blmf-combinations-for-patients-with-relapsedrefractory-multiple-myeloma/ 2025-07-17T21:08:37.783Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsedrefractory-multiple-myeloma/ 2025-07-23T16:06:20.423Z https://us.gsk.com/en-us/media/press-releases/gsk-sponsors-2025-national-senior-games-as-part-of-sideline-rsv-campaign-to-raise-awareness-of-rsv-in-older-adults/ 2025-07-24T13:34:38.02Z https://us.gsk.com/en-us/media/press-releases/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhea/ 2025-08-11T13:00:02.417Z https://us.gsk.com/en-us/media/press-releases/gsk-to-invest-30-billion-in-rd-and-manufacturing-in-the-united-states-over-next-5-years/ 2025-09-16T23:04:46.297Z https://us.gsk.com/en-us/media/press-releases/gsk-to-submit-label-update-for-wellcovorin-leucovorin-at-us-fda-s-request/ 2025-09-30T13:54:03.06Z https://us.gsk.com/en-us/media/press-releases/new-local-data-in-gsk-and-iqvias-vaccine-track/ 2025-10-01T14:02:47.57Z https://us.gsk.com/en-us/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-as-oral-option-for-treatment-of-uncomplicated-urogenital-gonorrhea-ugc/ 2025-12-12T15:41:09.653Z https://us.gsk.com/en-us/media/press-releases/gsk-celebrates-2025-impact-award-winners/ 2025-11-11T14:23:36.37Z https://us.gsk.com/en-us/media/press-releases/tesaro-a-gsk-subsidiary-initiates-litigation-against-anaptysbio-inc/ 2025-11-20T23:15:29.85Z https://us.gsk.com/en-us/media/press-releases/gsk-data-at-ash-show-potential-to-redefine-outcomes-for-people-living-with-blood-cancers/ 2025-12-01T16:55:44.477Z https://us.gsk.com/en-us/media/press-releases/gsk-227-a-b7-h3-targeted-antibody-drug-conjugate-granted-orphan-drug-designation-in-small-cell-lung-cancer-by-the-us-fda/ 2025-12-12T15:41:19.067Z https://us.gsk.com/en-us/media/press-releases/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-12-12T15:40:59.983Z https://us.gsk.com/en-us/media/press-releases/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma/ 2025-12-17T01:03:47.973Z https://us.gsk.com/en-us/media/press-releases/gsk-enters-agreement-with-us-government-to-lower-drug-prices-and-expand-access-to-respiratory-medicines-for-millions-of-americans/ 2025-12-19T20:14:29.507Z https://us.gsk.com/en-us/media/press-releases/gsk-announces-recipients-of-linked-by-lupus-optimal-care-initiative-grants-nearing-1-million/ 2026-01-20T15:03:04.897Z https://us.gsk.com/en-us/media/press-releases/gsk-awards-2m-in-coimmunity-initiative-grants-to-help-close-vaccination-gaps-commits-3m-for-2026/ 2026-01-21T14:57:51.597Z https://us.gsk.com/en-us/media/press-releases/gsk-s-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows/ 2026-02-18T13:18:58.573Z https://us.gsk.com/en-us/media/press-releases/gsk-s-rsv-vaccine-arexvy-approved-in-us-for-expanded-age-indication-in-adults-aged-18-49-years-at-increased-risk/ 2026-03-13T15:37:18.223Z https://us.gsk.com/en-us/media/media-contacts/ 2025-09-24T19:56:55.68Z https://us.gsk.com/en-us/media/in-focus/ 2025-09-04T13:33:57.43Z https://us.gsk.com/en-us/media/in-focus/flu-is-a-family-affair/ 2025-09-18T13:31:33.977Z https://us.gsk.com/en-us/media/in-focus/prosperar-despues-de-los-50/ 2025-06-19T15:38:56.993Z https://us.gsk.com/en-us/media/in-focus/gsk-2023-oncology-medical-congress/ 2025-07-01T16:41:49.09Z https://us.gsk.com/en-us/media/in-focus/gsk-2023-oncology-medical-congress/full-list-of-gsks-scientific-presentations/ 2025-06-19T15:38:55.837Z https://us.gsk.com/en-us/media/in-focus/no-permita-que-la-culebrilla-interrumpa-su-prosperidad/ 2025-06-19T15:38:52.273Z https://us.gsk.com/en-us/media/in-focus/five-for-five/ 2025-11-14T15:35:57.157Z https://us.gsk.com/en-us/careers/ 2026-04-02T11:42:23.307Z https://us.gsk.com/en-us/careers/search-jobs/ 2025-06-19T15:53:30.603Z https://us.gsk.com/en-us/careers/life-at-gsk/ 2025-06-19T15:53:39.78Z https://us.gsk.com/en-us/careers/life-at-gsk/employment-rights-under-federal-law/ 2025-06-19T15:53:47.1Z https://us.gsk.com/en-us/careers/experienced-professionals/ 2025-07-22T14:21:45.873Z https://us.gsk.com/en-us/careers/experienced-professionals/a-career-in-oncology/ 2025-08-06T13:56:51.973Z https://us.gsk.com/en-us/careers/experienced-professionals/a-career-in-boston/ 2026-04-02T10:45:18.883Z https://us.gsk.com/en-us/careers/early-careers/ 2025-09-08T19:58:51.737Z https://us.gsk.com/en-us/careers/early-careers/apprentices/ 2026-02-05T13:50:08.037Z https://us.gsk.com/en-us/careers/early-careers/internships-and-co-ops/ 2025-12-08T19:31:21.627Z https://us.gsk.com/en-us/careers/early-careers/scientific-leadership-program/ 2025-09-04T13:45:45.263Z https://us.gsk.com/en-us/careers/early-careers/commercial-development-program/ 2026-03-02T19:53:30.667Z https://us.gsk.com/en-us/careers/veterans-at-gsk/ 2025-09-04T16:24:07.467Z https://us.gsk.com/en-us/contact-us/ 2025-09-04T16:42:55.9Z https://us.gsk.com/en-us/business-to-business-in-the-us/ 2025-07-01T15:44:52.97Z https://us.gsk.com/en-us/terms-of-use/ 2025-07-01T14:21:44.353Z https://us.gsk.com/en-us/privacy-notice/ 2025-06-24T08:38:26.573Z https://us.gsk.com/en-us/legal-notices/ 2025-07-01T14:21:55.88Z https://us.gsk.com/en-us/gsk-employees/ 2025-06-19T15:52:44.413Z https://us.gsk.com/en-us/cookie-policy/ 2025-07-01T14:22:07Z https://us.gsk.com/en-us/accessibility/ 2025-06-24T11:07:21.767Z https://us.gsk.com/en-us/about-our-ads/ 2025-06-24T08:43:18.493Z https://us.gsk.com/en-us/report-a-possible-side-effect/ 2025-06-19T15:37:00.357Z https://us.gsk.com/en-us/behind-the-science-us-edition/ 2025-06-24T08:34:22.657Z https://us.gsk.com/en-us/behind-the-science-us-edition/immuno-oncology-integrating-innovation-into-standard-of-care-practice/ 2025-06-19T15:37:53.78Z https://us.gsk.com/en-us/behind-the-science-us-edition/are-they-the-same-atlantic-city-and-your-color-tv/ 2025-06-19T15:37:50.327Z https://us.gsk.com/en-us/behind-the-science-us-edition/the-right-diagnosis-and-treatment-brought-a-new-outlook/ 2025-06-19T15:37:54.573Z https://us.gsk.com/en-us/behind-the-science-us-edition/leading-the-way-to-inclusion-jigars-story/ 2025-06-24T15:24:46.543Z https://us.gsk.com/en-us/behind-the-science-us-edition/synthetic-lethality-outmaneuvering-the-cancer-genome/ 2025-06-24T15:25:06.1Z https://us.gsk.com/en-us/behind-the-science-us-edition/advancing-the-next-generation-of-immuno-oncology/ 2025-06-24T15:25:27.46Z https://us.gsk.com/en-us/behind-the-science-us-edition/the-role-of-eosinophils-in-our-immune-system/ 2025-06-24T15:26:03.913Z https://us.gsk.com/en-us/behind-the-science-us-edition/a-plan-in-pencil/ 2025-06-19T15:37:29.7Z https://us.gsk.com/en-us/behind-the-science-us-edition/don-t-settle-for-persistent-asthma-symptoms/ 2025-06-19T15:37:28.56Z https://us.gsk.com/en-us/behind-the-science-us-edition/who-was-percy-julian/ 2025-06-19T15:37:49.483Z https://us.gsk.com/en-us/behind-the-science-us-edition/gsk-hosts-first-protecting-our-communities-linkedin-live-series/ 2025-06-19T15:37:38.72Z https://us.gsk.com/en-us/behind-the-science-us-edition/gsk-hosts-second-protecting-our-communities-linkedin-live-event/ 2025-06-19T15:37:37.253Z https://us.gsk.com/en-us/behind-the-science-us-edition/breaking-barriers-for-better-copd-care/ 2025-07-02T10:09:55.253Z https://us.gsk.com/en-us/behind-the-science-us-edition/choosing-the-best-treatment-plan-for-you/ 2025-06-24T15:48:19.577Z https://us.gsk.com/en-us/behind-the-science-us-edition/breaking-the-stigma-of-copd/ 2025-06-24T15:48:01.56Z https://us.gsk.com/en-us/behind-the-science-us-edition/if-you-are-50-and-older-there-is-risk-for-shingles/ 2025-09-02T16:30:59.497Z https://us.gsk.com/en-us/behind-the-science-us-edition/linking-a-chapter-of-gsk-history-for-seeking-freedom/ 2025-06-19T15:37:55.397Z https://us.gsk.com/en-us/behind-the-science-us-edition/a-career-shift-to-further-progress-for-change/ 2025-06-19T15:37:43.113Z https://us.gsk.com/en-us/behind-the-science-us-edition/raising-the-bar-for-lupus-awareness-and-advancement-it-s-personal/ 2025-07-02T09:33:58.127Z https://us.gsk.com/en-us/behind-the-science-us-edition/seeing-multiple-myeloma-through-my-father-in-law-s-eyes/ 2025-06-19T15:37:35.697Z https://us.gsk.com/en-us/behind-the-science-us-edition/making-history-through-science/ 2025-06-19T15:37:34.817Z https://us.gsk.com/en-us/behind-the-science-us-edition/inspiring-the-next-generation-of-scientists/ 2025-06-24T15:48:42.94Z https://us.gsk.com/en-us/behind-the-science-us-edition/celebrating-our-pride-since-1996/ 2025-06-19T15:37:51.977Z https://us.gsk.com/en-us/behind-the-science-us-edition/gsk-named-best-place-to-work-for-disability-inclusion/ 2025-06-19T15:37:50.98Z https://us.gsk.com/en-us/behind-the-science-us-edition/asthma-management-it-s-time-to-get-personal/ 2025-09-02T16:25:38.937Z https://us.gsk.com/en-us/behind-the-science-us-edition/lunar-new-year-celebrating-our-culture-and-customs/ 2025-06-19T15:37:42.437Z https://us.gsk.com/en-us/behind-the-science-us-edition/gsk-recognized-by-disability-matters-for-workforce-practices-and-policies/ 2025-06-19T15:37:41.657Z https://us.gsk.com/en-us/behind-the-science-us-edition/gsk-recognized-for-showcasing-inclusion-in-practice-on-seramount-index/ 2025-06-19T15:37:40.167Z https://us.gsk.com/en-us/behind-the-science-us-edition/best-place-to-work-for-disability-inclusion/ 2025-06-19T15:37:27.88Z https://us.gsk.com/en-us/behind-the-science-us-edition/how-empathy-and-energy-make-this-erg-co-lead-a-success/ 2025-07-09T17:42:45.277Z https://us.gsk.com/en-us/behind-the-science-us-edition/women-in-science-nicole-godfrey/ 2025-07-09T17:41:32.683Z https://us.gsk.com/en-us/behind-the-science-us-edition/making-moves-to-build-a-career/ 2025-07-09T17:44:32.633Z https://us.gsk.com/en-us/behind-the-science-us-edition/meet-shreya-from-hot-pink-goggles-to-scientist/ 2025-09-02T16:29:48.07Z https://us.gsk.com/en-us/behind-the-science-us-edition/taking-care-of-the-chemo-lounge/ 2025-07-09T17:39:17.897Z https://us.gsk.com/en-us/behind-the-science-us-edition/in-service-of-country-and-company/ 2025-07-09T17:40:17.16Z https://us.gsk.com/en-us/behind-the-science-us-edition/opening-doors-for-others-through-mentorship/ 2025-07-09T17:37:54.13Z https://us.gsk.com/en-us/behind-the-science-us-edition/from-football-to-pharmacy/ 2025-06-24T15:21:40.627Z https://us.gsk.com/en-us/behind-the-science-us-edition/karen-evans-early-influences-with-long-term-impacts/ 2025-07-09T17:36:47.193Z https://us.gsk.com/en-us/behind-the-science-us-edition/gaining-a-deeper-understanding-of-myelofibrosis/ 2025-07-09T17:32:48.33Z https://us.gsk.com/en-us/behind-the-science-us-edition/the-science-of-giving/ 2025-09-02T16:32:42.777Z https://us.gsk.com/en-us/behind-the-science-us-edition/meet-beth-finding-her-seat-at-the-chemistry-bench/ 2025-12-05T13:09:00.457Z https://us.gsk.com/en-us/behind-the-science-us-edition/amruta-joshi-pangu-a-mother-with-a-purpose-in-science/ 2025-07-09T16:57:11.697Z https://us.gsk.com/en-us/behind-the-science-us-edition/addressing-long-standing-barriers-to-adult-immunization/ 2025-09-02T16:27:32.833Z https://us.gsk.com/en-us/behind-the-science-us-edition/creating-a-culture-of-holistic-care-in-lupus/ 2025-09-02T16:28:36.3Z https://us.gsk.com/en-us/behind-the-science-us-edition/andrea-acevedo-from-stargazing-to-discovering-life-changing-medicine/ 2025-07-09T16:55:03.19Z https://us.gsk.com/en-us/behind-the-science-us-edition/one-veterans-journey-of-service-and-success/ 2025-07-09T16:52:41.327Z https://us.gsk.com/en-us/behind-the-science-us-edition/dont-let-shingles-interrupt-your-plans-learn-more-about-your-risk/ 2026-02-23T21:54:33.787Z https://us.gsk.com/en-us/behind-the-science-us-edition/the-role-of-biomarkers-and-genetics-in-ovarian-cancer-five-facts/ 2025-06-23T10:56:54.117Z https://us.gsk.com/en-us/behind-the-science-us-edition/coimmunity-grants-provide-a-ground-level-boost-to-vaccine-advocacy/ 2025-06-19T15:37:08.22Z https://us.gsk.com/en-us/behind-the-science-us-edition/meet-ben-from-drug-discovery-to-leading-innovation-in-boston/ 2025-09-02T16:22:37.65Z https://us.gsk.com/en-us/behind-the-science-us-edition/surviving-the-storm-a-familys-battle-with-rotavirus/ 2025-06-19T15:37:06.377Z https://us.gsk.com/en-us/behind-the-science-us-edition/behind-the-scenes-and-behind-the-science-with-our-science-scale-symposium/ 2025-08-14T19:15:59.343Z https://us.gsk.com/en-us/behind-the-science-us-edition/empower-your-life-learn-how-reducing-inflammation-is-key-to-managing-copd-and-asthma-flare-ups/ 2025-12-12T15:48:38.137Z https://us.gsk.com/en-us/behind-the-science-us-edition/meet-rachel-a-vaccine-epidemiologist/ 2025-09-05T13:49:48.227Z https://us.gsk.com/en-us/behind-the-science-us-edition/meet-renuka-a-principal-scientist-fighting-infectious-diseases/ 2025-09-05T14:58:42.757Z https://us.gsk.com/en-us/behind-the-science-us-edition/a-national-tv-special-inspiring-older-adults-to-join-the-health-revolution-and-know-their-risk-for-rsv/ 2025-09-04T19:49:31.73Z https://us.gsk.com/en-us/behind-the-science-us-edition/a-new-horizon-advancing-possibilities-for-severe-asthma/ 2025-12-19T16:50:47.59Z https://us.gsk.com/en-us/behind-the-science-us-edition/understanding-multiple-myeloma-a-visual-guide/ 2026-03-19T15:59:23.843Z https://us.gsk.com/en-us/search/ 2025-09-08T19:46:47.99Z https://us.gsk.com/en-us/locations/ 2025-06-19T15:37:00.937Z https://us.gsk.com/en-us/error-404/ 2025-06-19T15:38:37.17Z https://us.gsk.com/en-us/sitemap/ 2025-06-24T08:32:04.087Z https://us.gsk.com/en-us/digital-sustainability/ 2025-06-19T15:36:59.807Z